Issue 1/2013
Content (30 Articles)
Assessing the in vivo efficacy of biologic antiangiogenic therapies
Peter M. Wilson, Melissa J. LaBonte, Heinz-Josef Lenz
Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer
Melis Kartal Yandım, Elif Apohan, Yusuf Baran
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors
Michael S. Gordon, Robert Ilaria Jr., Dinesh P. de Alwis, David S. Mendelson, Scott McKane, Margaret M. Wagner, Katherine Y. Look, Patricia M. LoRusso
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
Hitoshi Kusaba, Taito Esaki, Junji Kishimoto, Keita Uchino, Shuji Arita, Hozumi Kumagai, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
John Nemunaitis, Alain Mita, Joe Stephenson, Monica M. Mita, John Sarantopoulos, Swami Padmanabhan-Iyer, Nisha Nanda, Lyon Gleich, Annie-Claude Benichou, Adam Craig
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation
Yoon-Koo Kang, Byung Woog Kang, Seock-Ah Im, Jae-Lyun Lee, Sook Ryun Park, Won Ki Kang, Heung Moon Chang, Tae Won Kim, Do-Youn Oh, Kyung Hae Jung, Min-Hee Ryu
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
Bojana Milojkovic Kerklaan, Veronique Diéras, Christophe Le Tourneau, Marja Mergui-Roelvink, Alwin D. R. Huitema, Hilde Rosing, Jos H. Beijnen, Sandrine Marreaud, Anne-Sophie Govaerts, Martine J. Piccart-Gebhart, Jan H. M. Schellens, Ahmad Awada
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer
Francisco J. Esteva, Stacy L. Moulder, Ana M. Gonzalez-Angulo, Joe Ensor, James L. Murray, Marjorie C. Green, Kimberly B. Koenig, Mong-Hong Lee, Gabriel N. Hortobagyi, Sai-Ching Yeung
Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines
Robert A. Parise, Bean N. Anyang, Julie L. Eiseman, Merrill J. Egorin, Joseph M. Covey, Jan H. Beumer
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Yumiko Satoh, Daiya Takai, Tsuyoshi Hamada, Rie Uchino, Suguru Mizuno, Koji Miyabayashi, Dai Mohri, Kazumichi Kawakubo, Hirofumi Kogure, Natsuyo Yamamoto, Naoki Sasahira, Kenji Hirano, Hideaki Ijichi, Minoru Tada, Yutaka Yatomi, Kazuhiko Koike
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
Ruth Plummer, Ayman Madi, Melinda Jeffels, Heike Richly, Bahar Nokay, Stephen Rubin, Howard A. Ball, Steve Weller, Jeffrey Botbyl, Diana M. Gibson, Max E. Scheulen
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Jian Zhang, Shi-Yang Gu, Yu Gan, Zhong-Hua Wang, Bi-Yun Wang, Hai-Yi Guo, Jia-Lei Wang, Lei-Ping Wang, Xin-Min Zhao, Xi-Chun Hu
Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
B. F. Chu, M. J. Karpenko, Z. Liu, J. Aimiuwu, M. A. Villalona-Calero, K. K. Chan, M. R. Grever, G. A. Otterson
Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects
Richat Abbas, Stephan Chalon, Cathie Leister, Myriam El Gaaloul, Daryl Sonnichsen
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
Edna F. Choo, Chee M. Ng, Leanne Berry, Marcia Belvin, Nicholas Lewin-Koh, Mark Merchant, Laurent Salphati
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor
Yuehong Cui, Qian Li, Yiyi Yu, Yong Chen, Yi Feng, Yan Wang, Tianshu Liu
Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response
Nicolay V. Litviakov, Nadezhda V. Cherdyntseva, Matvey M. Tsyganov, Evgeny V. Denisov, Evgeny Y. Garbukov, Marina K. Merzliakova, Victor V. Volkomorov, Sergey V. Vtorushin, Marina V. Zavyalova, Elena M. Slonimskaya, Vladimir M. Perelmuter
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis
Mi Sung Park, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Chae Yoon Chon, Jinsil Seong
Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients
T. Miyahara, S. Mochinaga, S. Kimura, N. Aragane, T. Yakabe, S. Morita, K. Okudaira, H. Fujito
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial
Patrick A. Ott, Jason Chang, Kathleen Madden, Rajni Kannan, Caroline Muren, Crystal Escano, Xin Cheng, Yongzhao Shao, Sandra Mendoza, Alex Gandhi, Leonard Liebes, Anna C. Pavlick
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential
Patricia M. LoRusso, Sarina A. Piha-Paul, Monica Mita, A. Dimitrios Colevas, Vikram Malhi, Dawn Colburn, Ming Yin, Jennifer A. Low, Richard A. Graham
Erlotinib in patients with advanced lung squamous cell carcinoma
Chi-Lu Chiang, Chun-Ming Tsai, Teh-Ying Chou, Yuh-Min Chen, Shinn-Liang Lai, Jen-Fu Shih, Chao-Hua Chiu, Yu-Chin Lee
Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia
Poe-Hirr Hsyu, Diane R. Mould, Richard N. Upton, Michael Amantea
Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers
Ophelia Q. P. Yin, Véronique Bédoucha, Tracey McCulloch, Cheng Zheng, Wei Zhou, Azra Hussaini, Steven Novick
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
Toshihiko Doi, Atsushi Ohtsu, Nozomu Fuse, Takayuki Yoshino, Makoto Tahara, Kazuhiro Shibayama, Takatoshi Takubo, David M. Weinreich
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
K. N. Chi, A. Tolcher, P. Lee, P. J. Rosen, C. K. Kollmannsberger, K. P. Papadopoulos, A. Patnaik, A. Molina, J. Jiao, C. Pankras, B. Kaiser, A. Bernard, N. Tran, M. Acharya
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
K. Pliarchopoulou, K. T. Kalogeras, R. Kronenwett, R. M. Wirtz, A. G. Eleftheraki, A. Batistatou, M. Bobos, N. Soupos, G. Polychronidou, H. Gogas, E. Samantas, C. Christodoulou, T. Makatsoris, N. Pavlidis, D. Pectasides, G. Fountzilas
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
Gerardo Rosati, Antonio Avallone, Giuseppe Aprile, Alfredo Butera, Giorgio Reggiardo, Domenico Bilancia
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis
Jian Chen, Yun Ye, Haozhen Sun, Genming Shi
Hemodialysis no reason to withhold everolimus
J. M. van Rooijen, E. G. E. de Vries